Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients
- PMID: 25739496
- PMCID: PMC4470321
- DOI: 10.1002/cncr.29324
Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients
Abstract
Background: It is unknown whether immunosuppression results in more aggressive, advanced stage cancers. Because cancer stage is influenced both by tumor biology and medical surveillance, the authors assessed cancer stage in individuals infected with the human immunodeficiency virus (HIV) and solid organ transplant recipients, 2 immunosuppressed groups with differences in their health care use.
Methods: The authors used data on all cases of 15 cancer types diagnosed during 1996 through 2010 in 2 studies that linked US cancer registries with HIV and transplant registries. Odds ratios (ORs) for advanced (vs local) disease were estimated comparing HIV and transplant populations with immunocompetent individuals in polytomous logistic regression models adjusted for age, sex, race, registry, and year.
Results: A total of 8411 of 4.5 million cancer cases occurred in HIV-infected individuals and 7322 of 6.4 million cancer cases occurred in transplant recipients. Compared with immunocompetent patients with cancer, those infected with HIV were more likely to be diagnosed with distant stage lung (OR, 1.13), female breast (OR, 1.99), and prostate (OR, 1.57) cancers, whereas transplant recipients had fewer distant stage lung (OR, 0.54), female breast (OR, 0.75), and prostate (OR, 0.72) cancers. Both immunosuppressed populations had a shift toward advanced stage melanoma (ORs of 1.97 for HIV-infected individuals and 1.82 for transplant recipients) and bladder cancer (ORs of 1.42 for HIV-infected individuals and 1.54 for transplant recipients).
Conclusions: Bladder cancer and melanoma were more likely to be diagnosed at a nonlocal stage in both HIV-infected individuals and transplant recipients, suggesting a role for immunosuppression in their progression. In addition, we observed a shift for some common cancers toward later stages in HIV-infected individuals and toward earlier stages in transplant recipients, which is consistent with differential access to medical care or surveillance.
Keywords: cancer; human immunodeficiency virus (HIV); stage; transplant.
© 2015 American Cancer Society.
Figures

References
-
- Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. - PubMed
-
- Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87:1347–1359. - PubMed
-
- Berretta M, Cappellani A, Di BF, et al. Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. Onkologie. 2009;32:319–324. - PubMed
-
- Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin.Colorectal Cancer. 2009;8:215–219. - PubMed
-
- Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 2006;43:47–55. - PubMed
Publication types
MeSH terms
Grants and funding
- U58 DP003931/DP/NCCDPHP CDC HHS/United States
- 5U62PS004015/PS/NCHHSTP CDC HHS/United States
- U62 PS004011/PS/NCHHSTP CDC HHS/United States
- 5458DP003920/DP/NCCDPHP CDC HHS/United States
- U58 DP003920/DP/NCCDPHP CDC HHS/United States
- U58 DP000807/DP/NCCDPHP CDC HHS/United States
- 1U58 DP000807-01/DP/NCCDPHP CDC HHS/United States
- Z99 CA999999/ImNIH/Intramural NIH HHS/United States
- 5U58DP003875-01/DP/NCCDPHP CDC HHS/United States
- U62 PS001005/PS/NCHHSTP CDC HHS/United States
- U62 PS004001/PS/NCHHSTP CDC HHS/United States
- 5U58DP003883-03/DP/NCCDPHP CDC HHS/United States
- HHSN261201000037C/CA/NCI NIH HHS/United States
- 5U58DP000824-04/DP/NCCDPHP CDC HHS/United States
- N01-PC-35142/PC/NCI NIH HHS/United States
- N01-PC-35137/PC/NCI NIH HHS/United States
- U58 DP003883/DP/NCCDPHP CDC HHS/United States
- N01 PC035143/CA/NCI NIH HHS/United States
- N01-PC-35139/PC/NCI NIH HHS/United States
- 5U62PS004011-02/PS/NCHHSTP CDC HHS/United States
- U58DP000832/DP/NCCDPHP CDC HHS/United States
- U58 DP003875/DP/NCCDPHP CDC HHS/United States
- U58DP003879/DP/NCCDPHP CDC HHS/United States
- U62PS004001-2/PS/NCHHSTP CDC HHS/United States
- U58 DP000848-04/DP/NCCDPHP CDC HHS/United States
- P30 CA086862/CA/NCI NIH HHS/United States
- N01-PC-2013-00021/PC/NCI NIH HHS/United States
- HHSN261201000036C/CA/NCI NIH HHS/United States
- U58 DP003879/DP/NCCDPHP CDC HHS/United States
- U58DP12-1205 3919-03/DP/NCCDPHP CDC HHS/United States
- N01 PC035139/CA/NCI NIH HHS/United States
- 5U58/DP003931-02/DP/NCCDPHP CDC HHS/United States
- N01 PC035137/CA/NCI NIH HHS/United States
- 5U62PS001005-0/PS/NCHHSTP CDC HHS/United States
- N01 PC035142/CA/NCI NIH HHS/United States
- HHSN261201300021C/CA/NCI NIH HHS/United States
- HHSN261201000035I/CA/NCI NIH HHS/United States
- U58 DP000848/DP/NCCDPHP CDC HHS/United States
- U62 PS004015/PS/NCHHSTP CDC HHS/United States
- 5U58DP003921-03/DP/NCCDPHP CDC HHS/United States
- HHSN261201000024C/CA/NCI NIH HHS/United States
- HHSN261201000035C/PC/NCI NIH HHS/United States
- HHSN261201000034C/CA/NCI NIH HHS/United States
- U58 DP003921/DP/NCCDPHP CDC HHS/United States
- U58 DP000832/DP/NCCDPHP CDC HHS/United States
- HHSN261201000026C/CA/NCI NIH HHS/United States
- N01-PC-35143/PC/NCI NIH HHS/United States
- U58 DP000824/DP/NCCDPHP CDC HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical